351 related articles for article (PubMed ID: 35481923)
21. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
[TBL] [Abstract][Full Text] [Related]
22. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
[TBL] [Abstract][Full Text] [Related]
23. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract][Full Text] [Related]
24. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
[No Abstract] [Full Text] [Related]
26. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
Groves A; Cooney TM
Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.
Azad TD; Jin MC; Bernhardt LJ; Bettegowda C
Neurosurg Focus; 2020 Jan; 48(1):E9. PubMed ID: 31896079
[TBL] [Abstract][Full Text] [Related]
29. Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma.
Chen Y; Zhao C; Li S; Wang J; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765560
[TBL] [Abstract][Full Text] [Related]
30. H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics.
Rechberger JS; Power BT; Power EA; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023 Jan; 27(1):9-17. PubMed ID: 36744399
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Low-grade glioma with
Bernstock JD; Karandikar PV; Chen JA; Seidlitz J; Friedman GK; Meredith DM; Liu KX; Haas-Kogan D; Reardon DA; Peruzzi PP
Front Surg; 2024; 11():1356660. PubMed ID: 38840975
[TBL] [Abstract][Full Text] [Related]
32. Interdisciplinary care of children with diffuse midline glioma.
Coleman C; Chen K; Lu A; Seashore E; Stoller S; Davis T; Braunstein S; Gupta N; Mueller S
Neoplasia; 2023 Jan; 35():100851. PubMed ID: 36410226
[TBL] [Abstract][Full Text] [Related]
33. CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.
Das AK; Sinha M; Singh SK; Chaudhary A; Boro AK; Agrawal M; Bhardwaj S; Kishore S; Kumari K
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38669002
[TBL] [Abstract][Full Text] [Related]
34. A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
Zuo P; Li Y; Wang T; Lin X; Wu Z; Zhang J; Liao X; Zhang L
J Neurooncol; 2023 May; 163(1):159-171. PubMed ID: 37133743
[TBL] [Abstract][Full Text] [Related]
35. Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges.
Mandorino M; Maitra A; Armenise D; Baldelli OM; Miciaccia M; Ferorelli S; Perrone MG; Scilimati A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791893
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
Messinger D; Harris MK; Cummings JR; Thomas C; Yang T; Sweha SR; Woo R; Siddaway R; Burkert M; Stallard S; Qin T; Mullan B; Siada R; Ravindran R; Niculcea M; Dowling AR; Bradin J; Ginn KF; Gener MAH; Dorris K; Vitanza NA; Schmidt SV; Spitzer J; Li J; Filbin MG; Cao X; Castro MG; Lowenstein PR; Mody R; Chinnaiyan A; Desprez PY; McAllister S; Dun MD; Hawkins C; Waszak SM; Venneti S; Koschmann C; Yadav VN
Neuro Oncol; 2023 Jan; 25(1):54-67. PubMed ID: 35605606
[TBL] [Abstract][Full Text] [Related]
37. Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.
Parekh K; LeBlang S; Nazarian J; Mueller S; Zacharoulis S; Hynynen K; Powlovich L
Neoplasia; 2023 Mar; 37():100876. PubMed ID: 36709715
[TBL] [Abstract][Full Text] [Related]
38. Advances in Treatment of Diffuse Midline Gliomas.
Cacciotti C; Wright KD
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):849-856. PubMed ID: 37921944
[TBL] [Abstract][Full Text] [Related]
39. Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies.
Liu G; Qiu Y; Zhang P; Chen Z; Chen S; Huang W; Wang B; Yu X; Guo D
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145510
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy: a promising approach for glioma treatment.
Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]